Form 4 for INSM INSMED Inc
Accepted 2026-01-06 00:00:00 ET · period of report 2026-01-02 · accession 0001401017-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-06 | 2026-01-02 | INSM | Schaeffer Orlov S Nicole | Chief People Strategy Off | A - Grant | — | +5,293 | 41.8K | +15% | — |
| D | 2026-01-06 | 2026-01-02 | INSM | Schaeffer Orlov S Nicole | Chief People Strategy Off | M - OptEx | $13.91 | +87.3K | 129.0K | +209% | +$1.21M |
| DM | 2026-01-06 | 2026-01-02 | INSM | Schaeffer Orlov S Nicole | Chief People Strategy Off | S - Sale+OE | $175.20 | -87.3K | 63.9K | -58% | -$15.29M |
| D | 2026-01-06 | 2026-01-02 | INSM | Schaeffer Orlov S Nicole | Chief People Strategy Off | A - Grant | $0.00 | +27.6K | 27.6K | New | $0 |
| D | 2026-01-06 | 2026-01-02 | INSM | Schaeffer Orlov S Nicole | Chief People Strategy Off | M - OptEx | $0.00 | -87.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-02 | A | A | 5,293 | — | 41,754 | D | — | — | (F1) Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested. (F2) Each RSU was granted on January 2, 2026 for no consideration. |
| 2 | Common | Common Stock | 2026-01-02 | M | A | 87,290 | $13.91 | 129,044 | D | — | — | |
| 3 | Common | Common Stock | 2026-01-02 | S | D | 31,030 | $174.28 | 98,014 | D | — | — | (F4) This is the weighted average sales price representing 31,030 shares sold at prices ranging from $173.67 to $174.66 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 4 | Common | Common Stock | 2026-01-02 | S | D | 12,832 | $176.08 | 51,079 | D | — | — | (F6) This is the weighted average sales price representing 12,832 shares sold at prices ranging from $175.67 to $176.62 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 5 | Common | Common Stock | 2026-01-02 | S | D | 9,125 | $177.17 | 41,954 | D | — | — | (F7) This is the weighted average sales price representing 9,125 shares sold at prices ranging from $176.68 to $177.67 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 6 | Common | Common Stock | 2026-01-02 | S | D | 200 | $177.78 | 41,754 | D | — | — | (F8) This is the weighted average sales price representing 200 shares sold at prices ranging from $177.72 to $177.84 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 7 | Common | Common Stock | 2026-01-02 | S | D | 34,103 | $175.17 | 63,911 | D | — | — | (F5) This is the weighted average sales price representing 34,103 shares sold at prices ranging from $174.67 to $175.65 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 8 | Derivative | Stock Option (right to buy) | 2026-01-02 | A | A | 27,600 | $0.00 | 27,600 | D | $177.12 · — to 2036-01-02 | 27,600 Common Stock | (F9) These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested. |
| 9 | Derivative | Stock Option (right to buy) | 2026-01-02 | M | D | 87,290 | $0.00 | 0 | D | $13.91 · — to 2029-01-03 | 87,290 Common Stock | (F10) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |